Purpose: Although remission can be achieved in 80% of children with acute myelogenous leukemia (AML), many patients experience relapse. Because interleukin-2 (IL-2) can induce remission in patients with overt evidence of AML, we hypothesized that IL-2 given to patients in first remission after intensive consolidation chemotherapy might prevent relapse. This study sought to determine whether such an approach was feasible.
ALTHOUGH INTENSIVE, timed-sequential induction therapy has improved postremission outcome, at least one third of patients who complete chemotherapy consolidation for acute myelogenous leukemia (AML) in remission can be expected to experience leukemic relapse.' Notably, a lower risk of subsequent leukemic relapse has been observed after allogeneic transplantation because of a graft-versusleukemia effect.
2 Because interleukin-2 (IL-2) has induced IL-2 and after completion of each of the two courses of IL-2. Results: Observed toxicities included fever (57%), vascular leak (48%), hypotension (38%), tachycardia (14%), rash (29%), septicemia (5%), thrombocytopenia (29%/6), elevated transaminase (14%), electrolyte disturbance (29%), and hyperglycemia (10%). No patient required cardiac pressors or transfer to an intensive care unit. All patients studied developed an increase in lymphocyte count, CD56 count, CD3 count, and slL-2RCo levels after treatment with IL-2.
Conclusion: This schedule of IL-2 was reasonably well tolerated by children with AML in first remission. After treatment, increased levels of slL-2Ra were observed. CCG is conducting a randomized prospective trial to assess the efficacy of IL-2 to prevent the relapse of AML (CCG-2961).
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clinical remissions in patients with overt evidence of AML, 3 -6 and administration of IL-2 after autologous marrow transplant is associated with a clinical syndrome that resembles graft-versus-host disease, 7 we and others hypothesized that treatment with IL-2 after remission induction and consolidation might lower the incidence of subsequent leukemic relapse.8-11 In this CCG study, we sought to determine whether such an approach was feasible. Patients who lacked an HLA-matched family member marrow donor first received a sequentially timed induction chemotherapy regimen followed by high-dose cytarabine consolidation. Children who completed therapy in remission were then eligible to receive IL-2. We describe here the safety of this IL-2 regimen and the immunologic responses of these patients.
PATIENTS AND METHODS

Protocol Design and Patient Selection
The IL-2 protocol, CCG-0941, was open for patient entry in April 1995 to selected CCG institutions (see Appendix) and closed March 1996. Patients were required to be enrolled onto the AML therapy protocol CCG-2941 and to be without evidence of leukemia after the completion of consolidation therapy. CCG-2941 opened in January 1995, and eligibility included children and adolescents greater than 1 month and less than 21 years of age with blood and marrow biopsy confirmation of AML, myelodysplastic syndrome (MDS), or granulocytic sarcoma. A five-drug cycle of dexamethasone, cytarabine, 6-thioguanine, etoposide, and idarubicin was administered over 4 days and repeated in an obligatory fashion after a 6-day rest, irrespective of the patient's hematologic status.' After completion of the first course of IL-2 AFTER CONSOLIDATION CHEMOTHERAPY FOR AML this induction, an identical second course was delivered. Daunorubicin was substituted for idarubicin during the second cycle of each course for several patients after the treatment protocol was amended in an effort to reduce observed toxicity. Patients who achieved remission (absolute neutrophil count [ANC] > 1,000/pL and platelet count of 100,000/pLL with < 5% blasts in a recovering bone marrow) after the second induction course, but who lacked an HLA-matched family member, received chemotherapy consolidation that consisted of two cycles of L-Asparaginase and high-dose cytarabine, followed by three doses of intrathecal therapy.
2
To participate in the IL-2 protocol CCG-0941, investigators from participating institutions were required to attend a tutorial session that described IL-2 administration and management of potential complications. Patients were required to have an ANC of 500/pL or greater, platelet count of 30,000/pL or greater, serum creatinine less than 2 times normal, total bilirubin 1.5 times normal or less, AST or ALT less than 2.5 times normal, a performance status of 0 or 1, a life expectancy of 2 months or greater, and no evidence of infection. Patients were not eligible for enrollment onto CCG-0941 if they received corticosteroids or growth factors during the 2-week interval before the start of IL-2 therapy or had symptoms associated with cardiac, pulmonary, or CNS disease. Patients could not have HIV antibody or hepatitis B antigen present at the time of enrollment onto CCG-0941. Informed consent was obtained from all patients in accordance with the institutional review boards of the participating institutions.
IL-2 Therapy
A recombinant IL-2 (Proleukin; Chiron/Cetus Corporation, Emeryville, CA) induction dose of 9 X 106 IU/m 2 daily was delivered by continuous intravenous infusion (CIV) for 4 consecutive days in the hospital. After a 4-day rest period, patients received a maintenance dose of 1.6 X 106 IU/m2 daily by CIV for 10 consecutive days, usually at home." The incidence of infections and any hematopoietic, gastrointestinal, hepatic, renal, cardiac, and CNS toxicity associated with IL-2 treatment was recorded. Toxicity was graded in accordance with the common criteria established by the National Cancer Institute." In the event that grade III toxicity occurred, treatment with IL-2 was discontinued until abnormal laboratory values returned to a baseline pretherapy level or grade I toxicity was recorded. At such a time, IL-2 was resumed at 50% of the initial dose. Ancillary therapy included prophylactic antibiotics (eg, vancomycin and a broad-spectrum antibacterial agent), acetaminophen, diphenhydramine, and indomethacin. Meperidine was given if chills developed, and either prochlorperazine or chlorpromazine was administered if patients developed nausea.
Immunologic Studies
Peripheral-blood specimens were collected immediately before the start of IL-2 therapy (baseline), 1 day after the completion of the 96-hour IL-2 induction infusion (postinduction) and 1 day after the completion of IL-2 maintenance (postmaintenance). The absolute lymphocyte count was determined and the percent of cells with surface expression of CD56 and CD3 antigens was measured by flow cytometry. Soluble IL-2 receptor cs-chain (slL-2Ra) levels were analyzed by ELISA assay (Immunotech, Westbrook, ME).
14 The concentration of sIL-2Ros was determined by use of the standard curve that ranged from 0 to 400 pmol/L. The sensitivity of this assay was 5 pmol/L.
Statistical Methods
The principal goal of this study was to assess the feasibility of administering IL-2 as postconsolidation therapy for patients in whom 915 AML was in remission after treatment on CCG-2961. A two-stage design was to be used for CCG-0941. All patients were evaluated for the occurrence of life-threatening or fatal events that were defined to be any grade IV toxicity or death attributable to IL-2 after the start of IL-2 therapy. A cohort of 15 patients was to be enrolled and evaluated for adverse toxic events. If two or more patients experienced such an event, enrollment was to be terminated and IL-2 considered not feasible to be given as postconsolidation therapy. Otherwise, enrollment was to be expanded to 40 patients. This design was chosen because it had 90% probability to identify as intolerable a therapy with an adverse event rate of 15%. All data current to April 1, 1997, were used in the analysis.
Medians and ranges for the immunologic measures were calculated for baseline, postinduction, and postmaintenance time points. The hypotheses of no change in median measure between baseline versus postinduction and baseline versus postmaintenance time points were assessed by use of the paired signed-rank test. ' 5 Each patient's pretreatment measurement was used as the baseline for the postinduction and the postmaintenance comparison.
RESULTS
Patient Enrollment
Of 51 patients who completed CCG-2941 in remission and who were available for enrollment onto CCG-0941, 21 (41%) were entered onto CCG-0941. The first cohort of 15 patients was entered and no adverse toxic events were noted. Study accrual was terminated after an additional 6 patients were entered because CCG-2941 closed to patient entry and no further patients were available for entry onto CCG-0941. All 21 patients enrolled were assessable for toxicity and none experienced an adverse toxic event as defined above. The 95% CI for adverse toxic event rate was 0% to 13%.
Patient Characteristics
The demographic characteristics of the patients are listed in Table 1 . Treatment with IL-2 was initiated at a median of 6.2 months from diagnosis (range, 4.6 to 10.8 months). The median time between completion of consolidation chemotherapy and initial administration of IL-2 was 2 weeks (range, < 1 to 6 weeks). The median length of hospitalization during IL-2 treatment was 6 days (range, 3 to 18 days). Although all 21 patients received the appropriate induction dose of IL-2, one patient received a maintenance dose that was 75% of the intended dose. In another patient, the tenth day of maintenance dosing was omitted after the child's central venous line was dislodged. With the exception of an additional 3-day delay between induction and maintenance that occurred in one patient who experienced a varicella exposure, all patients received IL-2 in accordance with the protocol's timing. These deviations from protocol were considered minor and all patients were included in the analysis. None of the patients required hospitalization in an intensive care unit and only 11 grade III events were observed. In a previous study of 52 predominantly adult patients who The majority of patients had fever and 10 of 21 patients had some degree of vascular leak syndrome' 6 (VLS; Table   2 ). One of the patients who experienced grade II VLS had a 10% weight gain. One patient experienced grade III hypotension. This incident resolved promptly after treatment with intravenous fluids. No patients experienced renal toxicity. All patients received one or two RBC transfusions to maintain a hematocrit of at least 35%. None of the patients required hospitalization in an intensive care unit or treatment with cardiac pressors.
SIEVERS ET AL
Immunologic Studies
Immunologic features were measured in most patients on baseline, postinduction, and postmaintenance time points. Specimens were not submitted on one patient. Selected measurements were missing on five other patients because of difficulties in arranging shipment of patient specimens or technical difficulties in specimen analysis.
Serum slL-2Rot levels increased from a median of 141.5 pmol/L before treatment with IL-2 to 1353.4 pmol/L after high-dose induction with IL-2 (P < .001; Table 3 and Fig 1) . After lower-dose maintenance IL-2, the serum sIL-2Rac levels were more than five-fold higher than pretreatment values, but were lower than the peak value obtained after high-dose IL-2. IL-2 induced lymphocytosis with a significant increase in absolute lymphocyte count and CD3 + and CD56+ subsets when assessed immediately after the termination of IL-2 therapy (P < .001; Table 3 ). received an identical dosage regimen of IL-2 gous stem-cell transplant, three required press tension associated with IL-2 induction." Alth tient on our study required pressor support, this reflect the lower median age of our study popula to their experience, a 48% incidence of vascu observed in our pediatric patients. IL-2 is a 15 kD MW cytokine produced by T after activation that modifies the function of a va of the immune system, including T cells, B ct killer (NK) cells, monocytes, and myeloid eler cally, the use of IL-2 has been associated with augmented NK numbers and function in pat variety of malignancies.
22 IL-2 has also bee induce reproducible, measurable antitumor res ticularly for patients with melanoma and renal activate antibody-dependent cellular cytotoxic e and activate effector lymphocytes capable of n lymphokine-activated killer effect in vitro.
-24
Peripheral-blood samples obtained after the IL-2 were analyzed in this multiinstitutional stu the lymphoid activation induced by IL-2 is ass after autolodramatic changes in the lymphocyte circulation pattern rs for hypobetween circulating and noncirculating pools, efforts to ough no paevaluate immune activation in IL-2-treated patients cannot may simply easily rely on quantitative assessment of lymphocyte numtion. Similar bers. 25 , 2 6 Instead, the sIL-2Ra level provides a serologic lar leak was assessment of systemic lymphoid activation that includes that composed of both circulating and noncirculating pools. lymphocytes
The high-affinity IL-2 receptor contains the alpha, beta, and riety of cells gamma chains of the IL-2 receptor complex. The alpha chain ells, naturalprovides high-affinity It-2 binding when complexed with nents. Clinithe beta and gamma receptor chains. 2 7 After IL-2 binding, reproducibly the alpha chain is cleaved, released into the serum, and can ients with a be detected by immuno-chemical assay.
14 n shown to Soluble IL-2Ra is a stable molecule that provides a ponses, parsensitive indication of immunologic activation. 28 , 29 We have cell cancer; previously shown that a 4-day course of IL-2 at doses ffector cells; equivalent to that used in the present study is associated with mediating the tenfold increases in sIL-2Ra levels that remain stable during a 24-to 48-hour period during which the circulating cessation of lymphocyte count undergoes massive fluctuation.1 4 Moreidy. Because over, serum sIL-2Rct levels from selected patients in phase I ociated with and II trials were directly correlated with the number of circulatin T It-2 recentor-bearine ceils and measnrnhle clini-I -.
.
cal parameters associated with IL-Z's biologic ettect.7 In the current study, mean serum sIL-2Ra levels increased 12-fold after the IL-2 induction dosing and remained fivefold higher than the pretreatment levels after the maintenance dosing (Fig 1) . In the ongoing, prospective, randomized trial, these serum sIL-2Ra levels will be correlated with clinical measurements of toxicity and antitumor effect. Because this was a relatively small study with a primary end point of toxicity, no definitive conclusion can be drawn with regard to whether treatment with IL-2 prevents relapse.
In summary. IL-2 was reasonablv well tolerated and its amiraio cosil resud in icreaed leel of administration consistently resulted in increased levels of slL-2Ra, a sensitive surrogate for immunologic activation. A prospective, randomized study is currently being undermbols represent taken to determine whether administration of IL-2 after IL-2 administraer maintenance completion of consolidation chemotherapy reduces the rate of subsequent relapse. r circulating IL-2 recentor-bearinp, cells and measurable clini-
